PPL-003

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NamePPL-003
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsUveitisXerophthalmiaNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPortage Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEygen IncPortage Biotech Inc
Active IndicationsN/A
Inactive IndicationsUveitisXerophthalmiaNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A